Intraperitoneal chemotherapy for epithelial ovarian cancer. Hua-His Wu, MD OB/GYN, VGH-TPE. Epithelial ovarian cancer. Standard therapy A maximum cytoreductive surgery followed by combination chemotherapy with paclitaxel and carboplatin A chemo-sensitive tumor However, most recur
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Hua-His Wu, MD
(有效 夠深 留得久)
Is a contrary phenomenon
(Modified from Markman M, Semin Oncol 1991)
IP C/T might increase the therapeutic index for small tumors confined to the peritoneal cavity
IP infusion of carboplatin is feasible not only as an IP regional therapy but also as a more reasonable route for systemic chemotherapy
(Speyer and Sorich, 1992)
(at dose level ≧ 60 mg/㎡, it can persist more than 1 wk with significant level wkly IP Taxol )
(Makhija et al, 2001)
IP carboplatin (AUC 6-7) + IV Taxol (175 mg/m2, 3hr)
(Morgan et al)
Is IP administration of carboplatin replacable to IP cisplatin as a less toxic alternative?
Is IP administration of paclitaxel necessary or IP administration of docetaxelacceptable?
What is the optimal number of IP treatment?
What is the optimal timing for the IP catheter placement and what is the optimal type and material?
Is IP C/T for ovarian cancer with bulky residual tumor as effective as those for small residual tumor?
How effective is IP C/T for retroperitoneal lymph node metastasis?